# A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

> **NCT00219128** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 671 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00219128
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 671 (ACTUAL)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219128, "A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00219128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*